{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:47:40Z","timestamp":1793674060847,"version":"4.5.1"},"reference-count":199,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Pseudomonas aeruginosa is a resilient Gram-negative pathogen frequently implicated in healthcare associated infections, particularly among immunocompromised individuals and those with chronic conditions such as cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), or cancer. It is well known for its high resistance to antibiotic treatment. This review briefly mentions P. aeruginosa\u2019s resistance mechanisms, biofilm formation, and virulence factors, while primarily focusing on treatment challenges and recent advancements in therapeutic strategies aimed at overcoming resistance. Covered are novel non-antibiotic interventions such as quorum sensing inhibitors, quorum quenching agents, iron chelators, lectin and efflux pump inhibitors, as well as antimicrobial peptides and nanoparticles. Traditional medicine, phytochemicals, and probiotics are also evaluated. Additionally, this review explores the development of a viable vaccine, bacteriophage therapy, lactoferrin-hypothiocyanite combination, and topical use of electrochemical scaffolds. This review emphasizes the need for extensive safety studies and in vivo validation of these emerging non-antibiotic therapeutic strategies to determine their efficacy, pharmacological behavior, and clinical feasibility before they can be translated into practice. Many of these emerging treatments could play a vital role in future combination therapies by enhancing the efficacy of existing antibiotics and countering resistance and virulence mechanisms. Advancing these approaches from laboratory to clinical application remains a major challenge, making the development of approved therapies or vaccines a critical scientific and public health priority.<\/jats:p>","DOI":"10.3390\/medicina62010163","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T15:52:57Z","timestamp":1768319577000},"page":"163","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Mechanisms of Pseudomonas aeruginosa Resilience Against Antibiotic Treatment and Outlooks of Emerging Treatment Strategies"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0726-3375","authenticated-orcid":false,"given":"Angelika","family":"Kr\u016bmi\u0146a","sequence":"first","affiliation":[{"name":"Department of Infectology, Riga Stradins University, 1007 Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indra","family":"Zelti\u0146a","sequence":"additional","affiliation":[{"name":"Department of Infectology, Riga Stradins University, 1007 Riga, Latvia"},{"name":"Riga East Clinical University Hospital, 1079 Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Simsone","sequence":"additional","affiliation":[{"name":"Department of Infectology, Riga Stradins University, 1007 Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emile","family":"Eulitz","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Riga Stradins University, 1007 Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3671-1213","authenticated-orcid":false,"given":"Aigars","family":"Reinis","sequence":"additional","affiliation":[{"name":"Department of Biology and Microbiology, Riga Stradins University, 1007 Riga, Latvia"},{"name":"Pauls Stradins Clinical University Hospital, 1002 Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1826-9230","authenticated-orcid":false,"given":"Ludmila","family":"V\u012bksna","sequence":"additional","affiliation":[{"name":"Department of Infectology, Riga Stradins University, 1007 Riga, Latvia"},{"name":"Riga East Clinical University Hospital, 1079 Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jinf.2016.11.008","article-title":"Intensive care unit-acquired pneumonia due to Pseudomonas aeruginosa with and without multidrug resistance","volume":"74","author":"Ferrer","year":"2017","journal-title":"J. Infect."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1007\/BF01644194","article-title":"Pseudomonas aeruginosa as a pathogen in opportunistic infections","volume":"15","author":"Dalhoff","year":"1987","journal-title":"Infection"},{"key":"ref_3","unstructured":"Wilson, M.G., and Pandey, S. (2025). \n            Pseudomonas aeruginosa\n          . StatPearl, StatPearls Publishing."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1164\/rccm.200408-1044SO","article-title":"Pathogen-host interactions in Pseudomonas aeruginosa pneumonia","volume":"171","author":"Sadikot","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Sanya, D.R.A., On\u00e9sime, D., Vizzarro, G., and Jacquier, N. (2023). Recent advances in therapeutic targets identification and development of treatment strategies towards Pseudomonas aeruginosa infections. BMC Microbiol., 23.","DOI":"10.1186\/s12866-023-02832-x"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S931","DOI":"10.1093\/clinids\/5.Supplement_5.S931","article-title":"Pathogenesis of Pseudomonas aeruginosa ocular diseases","volume":"5","author":"Kreger","year":"1983","journal-title":"Clin. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"100640","DOI":"10.1016\/j.drup.2019.07.002","article-title":"Antibiotic resistance in Pseudomonas aeruginosa\u2013Mechanisms, epidemiology and evolution","volume":"44","author":"Botelho","year":"2019","journal-title":"Drug Resist. Updat."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.cmi.2019.06.011","article-title":"Pseudomonas aeruginosa and risk of death and exacerbations in patients with chronic obstructive pulmonary disease: An observational cohort study of 22,053 patients","volume":"26","author":"Ingebrigtsen","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"R114","DOI":"10.1186\/cc5006","article-title":"Reappraisal of Pseudomonas aeruginosa hospital-acquired pneumonia mortality in the era of metallo-\u03b2-lactamase-mediated multidrug resistance: A prospective observational study","volume":"10","author":"Zavascki","year":"2006","journal-title":"Crit. Care"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Langendonk, R.F., Neill, D.R., and Fothergill, J.L. (2021). The building blocks of antimicrobial resistance in Pseudomonas aeruginosa: Implications for current resistance-breaking therapies. Front. Cell. Infect. Microbiol., 11.","DOI":"10.3389\/fcimb.2021.665759"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2006.03.011","article-title":"Mechanisms of antimicrobial resistance in bacteria","volume":"119","author":"Tenover","year":"2006","journal-title":"Am. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Elfadadny, A., Ragab, R.F., AlHarbi, M., Badshah, F., Ib\u00e1\u00f1ez-Arancibia, E., Farag, A., Hendawy, A.O., De los-Rios-Escalante, P.R., Aboubakr, M., and Zakai, S.A. (2024). Antimicrobial resistance of Pseudomonas aeruginosa: Navigating clinical impacts, current resistance trends, and innovations in breaking therapies. Front. Microbiol., 15.","DOI":"10.3389\/fmicb.2024.1374466"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2217\/fmb.10.125","article-title":"Pseudomonas aeruginosa biofilms in cystic fibrosis","volume":"5","author":"Ciofu","year":"2010","journal-title":"Futur. Microbiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"44","DOI":"10.5539\/ijb.v7n2p44","article-title":"Pseudomonas aeruginosa\u2014Pathogenesis and Pathogenic Mechanisms","volume":"7","author":"Alhazmi","year":"2015","journal-title":"Int. J. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"108782","DOI":"10.1016\/j.celrep.2021.108782","article-title":"Pseudomonas aeruginosa aggregates in cystic fibrosis sputum produce exopolysaccharides that likely impede current therapies","volume":"34","author":"Jennings","year":"2021","journal-title":"Cell Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s44259-024-00046-3","article-title":"Mechanisms of antimicrobial resistance in biofilms","volume":"2","author":"Liu","year":"2024","journal-title":"NPJ Antimicrob. Resist."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Kelly, J.B., Nolan, A.C., and Zeden, M.S. (2024). How can we escape the ESKAPEs: Antimicrobial resistance mechanisms and what lies ahead?. PLoS Pathog., 20.","DOI":"10.1371\/journal.ppat.1012270"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e00181-19","DOI":"10.1128\/CMR.00181-19","article-title":"Antimicrobial resistance in ESKAPE pathogens","volume":"33","author":"Forde","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Silva, V., Ara\u00fajo, S., Cani\u00e7a, M., Pereira, J.E., Igrejas, G., and Poeta, P. (2025). Caught in the ESKAPE: Wildlife as key players in the ecology of resistant pathogens in a One Health context. Diversity, 17.","DOI":"10.3390\/d17040220"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Litwin, A., Rojek, S., Go\u017adzik, W., and Duszy\u0144ska, W. (2021). Pseudomonas aeruginosa device-associated\u2014Healthcare-associated infections and its multidrug resistance at intensive care unit of University Hospital: Polish, 8.5-year, prospective, single-centre study. BMC Infect. Dis., 21.","DOI":"10.1186\/s12879-021-05883-5"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e00744-19","DOI":"10.1128\/AAC.00744-19","article-title":"The essential role of hypermutation in rapid adaptation to antibiotic stress","volume":"63","author":"Mehta","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Verdial, C., Serrano, I., Tavares, L., Gil, S., and Oliveira, M. (2023). Mechanisms of antibiotic and biocide resistance that contribute to Pseudomonas aeruginosa persistence in the hospital environment. Biomedicines, 11.","DOI":"10.3390\/biomedicines11041221"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1128\/AAC.02676-15","article-title":"Evolution of Pseudomonas aeruginosa antimicrobial resistance and fitness under low and high mutation rates","volume":"60","author":"Cabot","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Schwartz, B., Klamer, K., Zimmerman, J., Kale-Pradhan, P.B., and Bhargava, A. (2024). Multidrug resistant Pseudomonas aeruginosa in clinical settings: A review of resistance mechanisms and treatment strategies. Pathogens, 13.","DOI":"10.3390\/pathogens13110975"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1017\/S0950268825100332","article-title":"Worldwide threatening prevalence of carbapenem-resistant Pseudomonas aeruginosa","volume":"153","author":"Ahmadi","year":"2025","journal-title":"Epidemiol. Infect."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Soltani, B., Ahmadrajabi, R., and Kalantar-Neyestanaki, D. (2024). Critical resistance to carbapenem and aminoglycosides in Pseudomonas aeruginosa: Spread of blaNDM\/16S methylase armA harboring isolates with intrinsic resistance mechanisms in Kerman, Iran. BMC Infect. Dis., 24.","DOI":"10.1186\/s12879-024-10085-w"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Glen, K.A., and Lamont, I.L. (2021). \u03b2-lactam resistance in Pseudomonas aeruginosa: Current status, future prospects. Pathogens, 10.","DOI":"10.3390\/pathogens10121638"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6248","DOI":"10.1128\/AAC.00825-15","article-title":"Mutations in \u03b2-lactamase AmpC increase resistance of Pseudomonas aeruginosa isolates to antipseudomonal cephalosporins","volume":"59","author":"Berrazeg","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/cid\/ciae332","article-title":"Rates of resistance to ceftazidime-avibactam and ceftolozane-tazobactam among patients treated for multidrug-resistant Pseudomonas aeruginosa bacteremia or pneumonia","volume":"80","author":"Shah","year":"2025","journal-title":"Clin. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e0279024","DOI":"10.1128\/spectrum.02790-24","article-title":"Antimicrobial susceptibility and resistance mechanisms to antipseudomonal \u03b2-lactams in Pseudomonas aeruginosa isolates from blood","volume":"13","author":"Murata","year":"2025","journal-title":"Microbiol. Spectr."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e0025622","DOI":"10.1128\/aac.00256-22","article-title":"New perspectives on antimicrobial agents: Imipenem-relebactam","volume":"66","author":"Lodise","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1093\/jac\/dkae263","article-title":"Impact of chromosomally encoded resistance mechanisms and transferable \u03b2-lactamases on the activity of cefiderocol and innovative \u03b2-lactam\/\u03b2-lactamase inhibitor combinations against Pseudomonas aeruginosa","volume":"79","author":"Maceiras","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Karruli, A., Catalini, C., D\u2019Amore, C., Foglia, F., Mari, F., Harxhi, A., Galdiero, M., and Durante-Mangoni, E. (2023). Evidence-based treatment of Pseudomonas aeruginosa infections: A critical reappraisal. Antibiotics, 12.","DOI":"10.3390\/antibiotics12020399"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Tamma, P.D., Heil, E.L., Justo, J.A., Mathers, A.J., Satlin, M.J., and Bonomo, R.A. (2024). Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections. Clin. Infect. Dis., ciad403.","DOI":"10.1093\/cid\/ciae403"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e0207925","DOI":"10.1128\/spectrum.02079-25","article-title":"Activity of cefiderocol against Pseudomonas aeruginosa from the USA and Europe (2020\u20132023) with difficult-to-treat resistance phenotype, including those nonsusceptible to recently developed \u03b2-lactam\/\u03b2-lactamase inhibitor combinations: Results from the SENTRY antimicrobial surveillance program","volume":"13","author":"Kimbrough","year":"2025","journal-title":"Microbiol. Spectr."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1128\/jb.152.2.636-642.1982","article-title":"Permeability of Pseudomonas aeruginosa outer membrane to hydrophilic solutes","volume":"152","author":"Yoshimura","year":"1982","journal-title":"J. Bacteriol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/2049-632X.12033","article-title":"Pseudomonas aeruginosa: New insights into pathogenesis and host defenses","volume":"67","author":"Gellatly","year":"2013","journal-title":"Pathog. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e14487","DOI":"10.1111\/1751-7915.14487","article-title":"Antibiotic influx and efflux in Pseudomonas aeruginosa: Regulation and therapeutic implications","volume":"17","author":"Wu","year":"2024","journal-title":"Microb. Biotechnol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Xavier, D.E., Pic\u00e3o, R.C., Girardello, R., Fehlberg, L.C.C., and Gales, A.C. (2010). Efflux pumps expression and its association with porin down-regulation and \u03b2-lactamase production among Pseudomonas aeruginosa causing bloodstream infections in Brazil. BMC Microbiol., 10.","DOI":"10.1186\/1471-2180-10-217"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Lorusso, A.B., Carrara, J.A., Barroso, C.D.N., Tuon, F.F., and Faoro, H. (2022). Role of efflux pumps on antimicrobial resistance in Pseudomonas aeruginosa. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232415779"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Avakh, A., Grant, G.D., Cheesman, M.J., Kalkundri, T., and Hall, S. (2023). The Art of War with Pseudomonas aeruginosa: Targeting Mex Efflux Pumps Directly to Strategically Enhance Antipseudomonal Drug Efficacy. Antibiotics, 12.","DOI":"10.3390\/antibiotics12081304"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1128\/AAC.45.6.1761-1770.2001","article-title":"Multidrug efflux pumps: Expression patterns and contribution to antibiotic resistance in Pseudomonas aeruginosa biofilms","volume":"45","author":"Parkins","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"865","DOI":"10.2174\/1381612805666230112185101","article-title":"OXA-type \u03b2-lactamases","volume":"5","author":"Naas","year":"1999","journal-title":"Curr. Pharm. Des."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Hu, M., and Chua, S.L. (2025). Antibiotic-Resistant Pseudomonas aeruginosa: Current Challenges and Emerging Alternative Therapies. Microorganisms, 13.","DOI":"10.3390\/microorganisms13040913"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1128\/AAC.05574-11","article-title":"Hypoxia increases antibiotic resistance in Pseudomonas aeruginosa through altering the composition of multidrug efflux pumps","volume":"56","author":"Schaible","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1126\/science.1211037","article-title":"Active starvation responses mediate antibiotic tolerance in biofilms and nutrient-limited bacteria","volume":"334","author":"Nguyen","year":"2011","journal-title":"Science"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Ciofu, O., and Tolker-Nielsen, T. (2019). Tolerance and resistance of Pseudomonas aeruginosa biofilms to antimicrobial agents\u2014How P. aeruginosa can escape antibiotics. Front. Microbiol., 10.","DOI":"10.3389\/fmicb.2019.00913"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1128\/AAC.47.4.1371-1375.2003","article-title":"MexXY-OprM efflux pump is necessary for adaptive resistance of Pseudomonas aeruginosa to aminoglycosides","volume":"47","author":"Hocquet","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s10096-015-2323-z","article-title":"Biofilm-specific antibiotic tolerance and resistance","volume":"34","author":"Olsen","year":"2015","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Uru\u00e9n, C., Chopo-Escuin, G., Tommassen, J., Mainar-Jaime, R.C., and Arenas, J. (2021). Biofilms as promoters of bacterial antibiotic resistance and tolerance. Antibiotics, 10.","DOI":"10.3390\/antibiotics10010003"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/emph\/eov018","article-title":"Horizontal gene transfer","volume":"1","author":"Burmeister","year":"2015","journal-title":"Evol. Med. Public Health"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e0069424","DOI":"10.1128\/spectrum.00694-24","article-title":"Characterization of acquired \u03b2-lactamases in Pseudomonas aeruginosa and quantification of their contributions to resistance","volume":"12","author":"Glen","year":"2024","journal-title":"Microbiol. Spectr."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Thacharodi, A., and Lamont, I.L. (2022). Aminoglycoside-Modifying Enzymes Are Sufficient to Make Pseudomonas aeruginosa Clinically Resistant to Key Antibiotics. Antibiotics, 11.","DOI":"10.3390\/antibiotics11070884"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.meegid.2013.10.027","article-title":"OprD mutations and inactivation in imipenem-resistant Pseudomonas aeruginosa isolates from China","volume":"21","author":"Fang","year":"2014","journal-title":"Infect. Genet. Evol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/978-3-031-08491-1_4","article-title":"Pseudomonas aeruginosa quorum sensing","volume":"1386","author":"Miranda","year":"2022","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_56","unstructured":"Demuth, D.R., and Lamont, R.J. (2006). Quorum sensing and regulation of Pseudomonas aeruginosa infections. Bacterial Cell-to-Cell Communication: Role in Virulence and Pathogenesis, Cambridge University Press."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Augustyniak, D., Olszak, T., and Drulis-Kawa, Z. (2022). Outer membrane vesicles (OMVs) of Pseudomonas aeruginosa provide passive resistance but not sensitization to LPS-specific phages. Viruses, 14.","DOI":"10.3390\/v14010121"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Bauman, S.J., and Kuehn, M.J. (2009). Pseudomonas aeruginosa vesicles associate with and are internalized by human lung epithelial cells. BMC Microbiol., 9.","DOI":"10.1186\/1471-2180-9-26"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2217\/fmb-2021-0158","article-title":"Pathogenic arsenal of Pseudomonas aeruginosa: An update on virulence factors","volume":"17","author":"Veetilvalappil","year":"2022","journal-title":"Futur. Microbiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000494069","article-title":"Bacteria-host crosstalk: Sensing of the quorum in the context of Pseudomonas aeruginosa infections","volume":"11","author":"Turkina","year":"2019","journal-title":"J. Innate Immun."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Zhang, X., Zhang, D., Zhou, D., Zheng, S., Li, S., Hou, Q., Li, G., and Han, H. (2025). A comprehensive review of the pathogenic mechanisms of Pseudomonas aeruginosa: Synergistic effects of virulence factors, quorum sensing, and biofilm formation. Front. Microbiol., 16.","DOI":"10.3389\/fmicb.2025.1619626"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"20983","DOI":"10.3390\/ijms141020983","article-title":"Biofilm matrix and its regulation in Pseudomonas aeruginosa","volume":"14","author":"Wei","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bcp.2016.10.001","article-title":"History of antimicrobial drug discovery: Major classes and health impact","volume":"133","author":"Aminov","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s40121-022-00591-2","article-title":"Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa","volume":"11","author":"Holger","year":"2022","journal-title":"Infect. Dis. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s13238-014-0100-x","article-title":"The hierarchy quorum sensing network in Pseudomonas aeruginosa","volume":"6","author":"Lee","year":"2015","journal-title":"Protein Cell"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Contreras, R. (2016). Is quorum sensing interference a viable alternative to treat Pseudomonas aeruginosa infections?. Front. Microbiol., 7.","DOI":"10.3389\/fmicb.2016.01454"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"K\u00f6hler, T., Perron, G.G., Buckling, A., and van Delden, C. (2010). Quorum Sensing Inhibition Selects for Virulence and Cooperation in Pseudomonas aeruginosa. PLoS Pathog., 6.","DOI":"10.1371\/journal.ppat.1000883"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1007\/s00253-019-09618-0","article-title":"Natural quorum sensing inhibitors effectively downregulate gene expression of Pseudomonas aeruginosa virulence factors","volume":"103","author":"Ahmed","year":"2019","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1099\/13500872-145-2-283","article-title":"Evidence that halogenated furanones from Delisea pulchra inhibit acylated homoserine lactone (AHL)-mediated gene expression by displacing the AHL signal from its receptor protein","volume":"145","author":"Manefield","year":"1999","journal-title":"Microbiology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3390\/md10010084","article-title":"Tasco\u00ae: A product of Ascophyllum nodosum enhances immune response of Caenorhabditis elegans against Pseudomonas aeruginosa infection","volume":"10","author":"Kandasamy","year":"2012","journal-title":"Mar. Drugs"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.3390\/s120404016","article-title":"Inhibition of quorum sensing-controlled virulence factor production in Pseudomonas aeruginosa PAO1 by Ayurveda spice clove (Syzygium aromaticum) bud extract","volume":"12","author":"Krishnan","year":"2012","journal-title":"Sensors"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Sarabhai, S., Sharma, P., and Capalash, N. (2013). Ellagic acid derivatives from Terminalia chebula Retz. downregulate the expression of quorum sensing genes to attenuate Pseudomonas aeruginosa PAO1 virulence. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0053441"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"100511","DOI":"10.1016\/j.phyplu.2023.100511","article-title":"Evaluation of antioxidant-rich bioactive plant extracts with special reference to Moringa oleifera Lam. for their interference to bacterial quorum sensing and biofilm","volume":"4","author":"Haris","year":"2024","journal-title":"Phytomedicine Plus"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1128\/AAC.00612-07","article-title":"Inhibition of quorum sensing-controlled virulence factor production in Pseudomonas aeruginosa by South Florida plant extracts","volume":"52","author":"Adonizio","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/cbdd.12478","article-title":"Antibiotic adjuvants: Diverse strategies for controlling drug-resistant pathogens","volume":"85","author":"Gill","year":"2015","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1093\/jac\/dkh223","article-title":"Synthetic furanones inhibit quorum-sensing and enhance bacterial clearance in Pseudomonas aeruginosa lung infection in mice","volume":"53","author":"Wu","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"8656","DOI":"10.1038\/srep08656","article-title":"6-Gingerol reduces Pseudomonas aeruginosa biofilm formation and virulence via quorum sensing inhibition","volume":"5","author":"Kim","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"9857","DOI":"10.1038\/s41598-017-09886-8","article-title":"A broad range quorum sensing inhibitor working through sRNA inhibition","volume":"7","author":"Jakobsen","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Deng, Y., Boon, C., Chen, S., Lim, A., and Zhang, L.-H. (2013). Cis-2-dodecenoic acid signal modulates virulence of Pseudomonas aeruginosa through interference with quorum sensing systems and T3SS. BMC Microbiol., 13.","DOI":"10.1186\/1471-2180-13-231"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"127861","DOI":"10.1016\/j.ijbiomac.2023.127861","article-title":"A review of chemical signaling pathways in the quorum sensing circuit of Pseudomonas aeruginosa","volume":"254","author":"Vadakkan","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1128\/AAC.00045-11","article-title":"Quorum sensing inhibitors increase the susceptibility of bacterial biofilms to antibiotics in vitro and in vivo","volume":"55","author":"Brackman","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1007\/s10096-024-04920-w","article-title":"An insight on the powerful of bacterial quorum sensing inhibition","volume":"43","author":"Naga","year":"2024","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_83","first-page":"102111","article-title":"Natural product-based inhibitors of quorum sensing: A novel approach to combat antibiotic resistance","volume":"43","author":"Alum","year":"2025","journal-title":"Biochem. Biophys. Rep."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Touati, A., Ibrahim, N.A., Tighilt, L., and Idres, T. (2025). Anti-QS strategies against Pseudomonas aeruginosa infections. Microorganisms, 13.","DOI":"10.3390\/microorganisms13081838"},{"key":"ref_85","first-page":"1753","article-title":"Modulating bacterial communication via quorum sensing inhibitors: A review of therapeutic potential","volume":"12","author":"Vishwakarma","year":"2025","journal-title":"Int. J. Innov. Res. Technol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2553787","DOI":"10.1080\/21505594.2025.2553787","article-title":"Ferroptosis and iron-based therapies in Pseudomonas aeruginosa infections: From pathogenesis to treatment","volume":"16","author":"Shao","year":"2025","journal-title":"Virulence"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1111\/1751-7915.14241","article-title":"Mechanisms of iron homeostasis in Pseudomonas aeruginosa and emerging therapeutics directed to disrupt this vital process","volume":"16","author":"Llamas","year":"2023","journal-title":"Microb. Biotechnol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/417552a","article-title":"A component of innate immunity prevents bacterial biofilm development","volume":"417","author":"Singh","year":"2002","journal-title":"Nature"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1099\/jmm.0.004416-0","article-title":"Iron-binding compounds impair Pseudomonas aeruginosa biofilm formation, especially under anaerobic conditions","volume":"58","author":"Sanderson","year":"2009","journal-title":"J. Med. Microbiol."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Vinuesa, V., and McConnell, M.J. (2021). Recent advances in iron chelation and gallium-based therapies for antibiotic resistant bacterial infections. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22062876"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1172\/JCI30783","article-title":"The transition metal gallium disrupts Pseudomonas aeruginosa iron metabolism and has antimicrobial and antibiofilm activity","volume":"117","author":"Kaneko","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1128\/AEM.72.3.2064-2069.2006","article-title":"Chelator-induced dispersal and killing of Pseudomonas aeruginosa cells in a biofilm","volume":"72","author":"Banin","year":"2006","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10534-020-00281-x","article-title":"Biofilm-specific uptake of a 4-pyridone-based iron chelator by Pseudomonas aeruginosa","volume":"34","author":"Houshmandyar","year":"2021","journal-title":"Biometals"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1165\/rcmb.2008-0299OC","article-title":"Tobramycin and FDA-approved iron chelators eliminate Pseudomonas aeruginosa biofilms on cystic fibrosis cells","volume":"41","author":"Stanton","year":"2009","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Mettrick, K., Hassan, K., Lamont, I., and Reid, D. (2020). The iron-chelator, N,N\u2019-bis (2-hydroxybenzyl) ethylenediamine-N,N\u2019-diacetic acid is an effective colistin adjunct against clinical strains of biofilm-dwelling Pseudomonas aeruginosa. Antibiotics, 9.","DOI":"10.3390\/antibiotics9040144"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1039\/C9MD00032A","article-title":"Connecting iron acquisition and biofilm formation in the ESKAPE pathogens as a strategy for combatting antibiotic resistance","volume":"10","author":"Post","year":"2019","journal-title":"Med. Chem. Commun."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.chembiol.2005.05.007","article-title":"Iron salts perturb biofilm formation and disrupt existing biofilms of Pseudomonas aeruginosa","volume":"12","author":"Musk","year":"2005","journal-title":"Chem. Biol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"16559","DOI":"10.1002\/anie.201709368","article-title":"Covalent lectin inhibition and application in bacterial biofilm imaging","volume":"56","author":"Wagner","year":"2017","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.biotechadv.2018.11.013","article-title":"Antibiotic resistance in Pseudomonas aeruginosa: Mechanisms and alternative therapeutic strategies","volume":"37","author":"Pang","year":"2019","journal-title":"Biotechnol. Adv."},{"key":"ref_100","unstructured":"Varki, A., Cummings, R.D., and Esko, J.D. (2022). Microbial Lectins: Hemagglutinins, Adhesins, and Toxins, Cold Spring Harbor Laboratory Press."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e202200081","DOI":"10.1002\/cmdc.202200081","article-title":"Structural considerations for building synthetic glycoconjugates as inhibitors for Pseudomonas aeruginosa lectins","volume":"17","author":"Wojtczak","year":"2022","journal-title":"ChemMedChem"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1128\/IAI.01204-08","article-title":"Role of LecA and LecB lectins in Pseudomonas aeruginosa-induced lung injury and effect of carbohydrate ligands","volume":"77","author":"Chemani","year":"2009","journal-title":"Infect. Immun."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"371","DOI":"10.7150\/ijms.5.371","article-title":"Inhalation with fucose and galactose for treatment of Pseudomonas aeruginosa in cystic fibrosis patients","volume":"5","author":"Hauber","year":"2008","journal-title":"Int. J. Med. Sci."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"10631","DOI":"10.1002\/anie.201104342","article-title":"A glycopeptide dendrimer inhibitor of the galactose-specific lectin LecA and of Pseudomonas aeruginosa biofilms","volume":"50","author":"Kadam","year":"2011","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"13333","DOI":"10.1039\/D4SC02703E","article-title":"Dual inhibitors of Pseudomonas aeruginosa virulence factors LecA and LasB","volume":"15","author":"Metelkina","year":"2024","journal-title":"Chem. Sci."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1039\/D2CS00954D","article-title":"Glycomimetics for the inhibition and modulation of lectins","volume":"52","author":"Leusmann","year":"2023","journal-title":"Chem. Soc. Rev."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"29","DOI":"10.32607\/20758251-2015-7-2-29-41","article-title":"Pseudomonas aeruginosa lectins as targets for novel antibacterials","volume":"7","author":"Grishin","year":"2015","journal-title":"Acta Naturae"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Zhang, L., Tian, X., Sun, L., Mi, K., Wang, R., Gong, F., and Huang, L. (2024). Bacterial efflux pump inhibitors reduce antibiotic resistance. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16020170"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"11392","DOI":"10.1038\/s41598-017-11892-9","article-title":"Effect of efflux pump inhibition on Pseudomonas aeruginosa transcriptome and virulence","volume":"7","author":"Rampioni","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1128\/AAC.00463-10","article-title":"Synergistic activities of an efflux pump inhibitor and iron chelators against Pseudomonas aeruginosa growth and biofilm formation","volume":"54","author":"Liu","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1089\/photob.2023.0005","article-title":"Phenylalanine-Arginine-\u03b2-Naphthylamide enhances the photobactericidal effect of methylene blue on Pseudomonas aeruginosa","volume":"41","author":"He","year":"2023","journal-title":"Photobiomodulation Photomed. Laser Surg."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1021\/acsinfecdis.7b00095","article-title":"Attaching the NorA efflux pump inhibitor INF55 to methylene blue enhances antimicrobial photodynamic inactivation of methicillin-resistant Staphylococcus aureus in vitro and in vivo","volume":"3","author":"Rineh","year":"2017","journal-title":"ACS Infect. Dis."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"115472","DOI":"10.1016\/j.addr.2024.115472","article-title":"A systematic overview of strategies for photosensitizer and light delivery in antibacterial photodynamic therapy for lung infections","volume":"215","author":"Shleeva","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2217\/fmb-2023-0208","article-title":"Repurposing approved drugs as potential efflux pump inhibitors in multidrug-resistant Pseudomonas aeruginosa","volume":"19","author":"Pereira","year":"2024","journal-title":"Future Microbiol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1093\/jac\/dky042","article-title":"Role of bacterial efflux pumps in biofilm formation","volume":"73","author":"Alav","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Rouvier, F., Brunel, J.-M., Pag\u00e8s, J.-M., and Vergalli, J. (2025). Efflux-mediated resistance in Enterobacteriaceae: Recent advances and ongoing challenges to inhibit bacterial efflux pumps. Antibiotics, 14.","DOI":"10.3390\/antibiotics14080778"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Khan, R.T., Sharma, V., Khan, S.S., and Rasool, S. (2024). Prevention and potential remedies for antibiotic resistance: Current research and future prospects. Front. Microbiol., 15.","DOI":"10.3389\/fmicb.2024.1455759"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Abusaiba, T.H.H., Hussein, A.A., and Almahbob, T.F. (2023). Inhibiting efflux pumps and resistance mechanisms: A mini review. Qeios, JHP92F.","DOI":"10.32388\/JHP92F"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.nut.2016.01.024","article-title":"In vitro bactericidal activity of promising nutraceuticals for targeting multidrug resistant Pseudomonas aeruginosa","volume":"32","author":"Chakotiya","year":"2016","journal-title":"Nutrition"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Semenescu, I., Avram, S., Similie, D., Minda, D., Diaconeasa, Z., Muntean, D., Lazar, A.E., Gurgus, D., and Danciu, C. (2024). Phytochemical, antioxidant, antimicrobial and safety profile of Glycyrrhiza glabra L. extract obtained from Romania. Plants, 13.","DOI":"10.3390\/plants13233265"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.micpath.2016.07.001","article-title":"Alternative to antibiotics against Pseudomonas aeruginosa: Effects of Glycyrrhiza glabra on membrane permeability and inhibition of efflux activity and biofilm formation in Pseudomonas aeruginosa and its in vitro time-kill activity","volume":"98","author":"Chakotiya","year":"2016","journal-title":"Microb. Pathog."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Wahab, S., Annadurai, S., Abullais, S.S., Das, G., Ahmad, W., Ahmad, M.F., Kandasamy, G., Vasudevan, R., Ali, M.S., and Amir, M. (2021). Glycyrrhiza glabra (Licorice): A comprehensive review on its phytochemistry, biological activities, clinical evidence and toxicology. Plants, 10.","DOI":"10.3390\/plants10122751"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4103\/2231-4040.79801","article-title":"Antibacterial activity of some Indian Ayurvedic preparations against enteric bacterial pathogens","volume":"2","author":"Tambekar","year":"2011","journal-title":"J. Adv. Pharm. Technol. Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"556","DOI":"10.7150\/ijbs.6.556","article-title":"Activity and interactions of antibiotic and phytochemical combinations against Pseudomonas aeruginosa in vitro","volume":"6","author":"Jayaraman","year":"2010","journal-title":"Int. J. Biol. Sci."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/ja.2007.45","article-title":"Antibacterial activity of allicin alone and in combination with \u03b2-lactams against Staphylococcus spp. and Pseudomonas aeruginosa","volume":"60","author":"Cai","year":"2007","journal-title":"J. Antibiot."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Vaou, N., Stavropoulou, E., Voidarou, C., Tsigalou, C., and Bezirtzoglou, E. (2021). Towards advances in medicinal plant antimicrobial activity: A review study on challenges and future perspectives. Microorganisms, 9.","DOI":"10.3390\/microorganisms9102041"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Kadam, S., Madhusoodhanan, V., Bandgar, A., and Kaushik, K.S. (2020). From Treatise to Test: Evaluating Traditional Remedies for Anti-Biofilm Potential. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.566334"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S1995-7645(10)60064-8","article-title":"Antibacterial activities of some plant extracts alone and in combination with different antimicrobials against multidrug-resistant Pseudomonas aeruginosa strains","volume":"3","author":"Adwan","year":"2010","journal-title":"Asian Pac. J. Trop. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jtcme.2017.05.008","article-title":"Attenuation of quorum-sensing-dependent virulence factors and biofilm formation by medicinal plants against antibiotic resistant Pseudomonas aeruginosa","volume":"8","author":"Ganesh","year":"2017","journal-title":"J. Tradit. Complement. Med."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Dharmaratne, M.P.J., Manoraj, A., Thevanesam, V., Ekanayake, A., Kumar, N.S., Liyanapathirana, V., Abeyratne, E., and Bandara, B.M.R. (2018). Terminalia bellirica fruit extracts: In-vitro antibacterial activity against selected multidrug-resistant bacteria, radical scavenging activity and cytotoxicity study on BHK-21 cells. BMC Complement. Altern. Med., 18.","DOI":"10.1186\/s12906-018-2382-7"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"7","DOI":"10.51470\/PSR.2024.05.02.07","article-title":"Phytochemical profiling and microbial targeting of medicinal plants in the development of alternative antimicrobial therapies","volume":"5","author":"Vinayaka","year":"2024","journal-title":"Plant Sci. Rev."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4161\/hv.34296","article-title":"Vaccination against respiratory Pseudomonas aeruginosa infection","volume":"11","author":"Grimwood","year":"2015","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Killough, M., Rodgers, A.M., and Ingram, R.J. (2022). Pseudomonas aeruginosa: Recent advances in vaccine development. Vaccines, 10.","DOI":"10.3390\/vaccines10071100"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1089\/sur.2018.233","article-title":"Progress toward the elusive Pseudomonas aeruginosa vaccine","volume":"19","author":"Merakou","year":"2018","journal-title":"Surg. Infect."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1080\/21645515.2019.1650999","article-title":"Immunological considerations in the development of Pseudomonas aeruginosa vaccines","volume":"16","author":"Baker","year":"2020","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Santamarina-Fern\u00e1ndez, R., Fuentes-Valverde, V., Silva-Rodr\u00edguez, A., Garc\u00eda, P., Moscoso, M., and Bou, G. (2025). Pseudomonas aeruginosa Vaccine Development: Lessons, Challenges, and Future Innovations. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26052012"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Sousa, S.A., Seixas, A.M.M., Marques, J.M.M., and Leit\u00e3o, J.H. (2021). Immunization and immunotherapy approaches against Pseudomonas aeruginosa and Burkholderia cepacia complex infections. Vaccines, 9.","DOI":"10.3390\/vaccines9060670"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"5689709","DOI":"10.1155\/2017\/5689709","article-title":"Immunization with bivalent flagellin protects mice against fatal Pseudomonas aeruginosa pneumonia","volume":"2017","author":"Behrouz","year":"2017","journal-title":"J. Immunol. Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/apm.12337","article-title":"Immunological evaluation of an alginate-based conjugate as a vaccine candidate against Pseudomonas aeruginosa","volume":"123","author":"Farjah","year":"2015","journal-title":"APMIS"},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Elbehiry, A., and Abalkhail, A. (2025). Antimicrobial nanoparticles against superbugs: Mechanistic insights, biomedical applications, and translational frontiers. Pharmaceuticals, 18.","DOI":"10.3390\/ph18081195"},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Franco, D., Calabrese, G., Guglielmino, S.P.P., and Conoci, S. (2022). Metal-Based Nanoparticles: Antibacterial Mechanisms and Biomedical Application. Microorganisms, 10.","DOI":"10.3390\/microorganisms10091778"},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Mouzakis, A., Panagopoulos, P., Papazoglou, D., and Petrakis, V. (2025). A comprehensive review of nanoparticles in the fight against antimicrobial resistance. Pathogens, 14.","DOI":"10.3390\/pathogens14111090"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1039\/D4PM00032C","article-title":"Antimicrobial nanoparticles: Current landscape and future challenges","volume":"1","author":"Mondal","year":"2024","journal-title":"RSC Pharm."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"16074","DOI":"10.1038\/s41598-019-52473-2","article-title":"Synergistic antibacterial effects of metallic nanoparticle combinations","volume":"9","author":"Bankier","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"106854","DOI":"10.1016\/j.micpath.2024.106854","article-title":"Antibacterial and antibiofilm effect of zinc oxide nanoparticles on Pseudomonas aeruginosa variants isolated from young patients with cystic fibrosis","volume":"195","author":"Konkuri","year":"2024","journal-title":"Microb. Pathog."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"13535","DOI":"10.1039\/D4RA00631C","article-title":"Nanoparticles incorporated hydrogels for delivery of antimicrobial agents: Developments and trends","volume":"14","author":"Ahmad","year":"2024","journal-title":"RSC Adv."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1109\/TNB.2023.3268138","article-title":"Antibacterial and anti-biofilm activities of microbial synthesized silver and magnetic iron oxide nanoparticles against Pseudomonas aeruginosa","volume":"22","author":"Esfahani","year":"2023","journal-title":"IEEE Trans. Nanobiosci."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"12879","DOI":"10.2147\/IJN.S557649","article-title":"Antimicrobial mechanisms of metal-based nanomaterials","volume":"20","author":"Liao","year":"2025","journal-title":"Int. J. Nanomed."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"6905631","DOI":"10.1155\/2020\/6905631","article-title":"Nanoparticulate antibiotic systems as antibacterial agents and antibiotic delivery platforms to fight infections","volume":"2020","author":"Vassallo","year":"2020","journal-title":"J. Nanomater."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Caciandone, M., Niculescu, A.-G., Grumezescu, V., B\u00eerc\u0103, A.C., Ghica, I.C., Vasile, B.\u0218., Oprea, O., Nica, I.C., Stan, M.S., and Holban, A.M. (2022). Magnetite nanoparticles functionalized with therapeutic agents for enhanced ENT antimicrobial properties. Antibiotics, 11.","DOI":"10.3390\/antibiotics11050623"},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Costa, B.A., Abu\u00e7afy, M.P., Barbosa, T.W.L., da Silva, B.L., Fulindi, R.B., Isquibola, G., da Costa, P.I., and Chiavacci, L.A. (2023). ZnO@ZIF-8 nanoparticles as nanocarrier of ciprofloxacin for antimicrobial activity. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15010259"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"6612","DOI":"10.1039\/D5MA00487J","article-title":"A one health nanotechnology approach to address antimicrobial resistance: State-of-the-art and strategic outlook","volume":"6","author":"Desai","year":"2025","journal-title":"Mater. Adv."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Mercan, D.-A., Niculescu, A.-G., and Grumezescu, A.M. (2022). Nanoparticles for Antimicrobial Agents Delivery\u2014An Up-to-Date Review. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232213862"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Bernal-Mercado, A.T., Juarez, J., Valdez, M.A., Ayala-Zavala, J.F., Del-Toro-S\u00e1nchez, C.L., and Encinas-Basurto, D. (2022). Hydrophobic chitosan nanoparticles loaded with carvacrol against Pseudomonas aeruginosa biofilms. Molecules, 27.","DOI":"10.3390\/molecules27030699"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"7895","DOI":"10.2147\/IJN.S469724","article-title":"Antibiotic nanoparticles-loaded wound dressings against Pseudomonas aeruginosa\u2019s skin infection: A systematic review","volume":"19","author":"Botero","year":"2024","journal-title":"Int. J. Nanomed."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12941-020-00389-5","article-title":"Bacteriophage therapy against Pseudomonas aeruginosa biofilms: A review","volume":"19","author":"Chegini","year":"2020","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Abedon, S.T., Garc\u00eda, P., Mullany, P., and Aminov, R. (2017). Editorial: Phage Therapy: Past, Present and Future. Front. Microbiol., 8.","DOI":"10.3389\/fmicb.2017.00981"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1128\/aac.00578-23","article-title":"Phage-antibiotic combinations against multidrug-resistant Pseudomonas aeruginosa in in vitro static and dynamic biofilm models","volume":"67","author":"Holger","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"100245","DOI":"10.1016\/j.bioflm.2024.100245","article-title":"Combination of phages and antibiotics with enhanced killing efficacy against dual-species bacterial communities in a three-dimensional lung epithelial model","volume":"9","author":"Akturk","year":"2025","journal-title":"Biofilm"},{"key":"ref_160","first-page":"3653","article-title":"Bacteriophage-based therapy in cystic fibrosis-associated Pseudomonas aeruginosa infections: Rationale and current status","volume":"9","author":"Hraiech","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1128\/AAC.01646-08","article-title":"Antibacterial efficacy of phages against Pseudomonas aeruginosa infections in mice and Drosophila melanogaster","volume":"53","author":"Heo","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"5250040","DOI":"10.1155\/2023\/5250040","article-title":"Recent approaches for downplaying antibiotic resistance: Molecular mechanisms","volume":"2023","author":"Ahmed","year":"2023","journal-title":"BioMed Res. Int."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1086\/651135","article-title":"Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections","volume":"201","author":"Debarbieux","year":"2010","journal-title":"J. Infect. Dis."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"e02573-17","DOI":"10.1128\/AAC.02573-17","article-title":"Design of a broad-range bacteriophage cocktail that reduces Pseudomonas aeruginosa biofilms and treats acute infections in two animal models","volume":"62","author":"Forti","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1473-3099(18)30482-1","article-title":"Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): A randomised, controlled, double-blind phase 1\/2 trial","volume":"19","author":"Jault","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40560-024-00759-7","article-title":"Current status of bacteriophage therapy for severe bacterial infections","volume":"12","author":"Sawa","year":"2024","journal-title":"J. Intensiv. Care"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"5728","DOI":"10.1128\/JB.01184-12","article-title":"The CRISPR\/Cas adaptive immune system of Pseudomonas aeruginosa mediates resistance to naturally occurring and engineered phages","volume":"194","author":"Cady","year":"2012","journal-title":"J. Bacteriol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"16085","DOI":"10.1038\/nmicrobiol.2016.85","article-title":"Inactivation of CRISPR-Cas systems by anti-CRISPR proteins in diverse bacterial species","volume":"1","author":"Pawluk","year":"2016","journal-title":"Nat. Microbiol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/femsre\/fuaa017","article-title":"Current challenges and future opportunities of phage therapy","volume":"44","author":"Pires","year":"2020","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Dini, I., De Biasi, M.G., and Mancusi, A. (2022). An overview of the potentialities of antimicrobial peptides derived from natural sources. Antibiotics, 11.","DOI":"10.3390\/antibiotics11111483"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"10488","DOI":"10.1038\/s41467-025-65449-w","article-title":"An antimicrobial peptide as a potential therapy for bacterial pneumonia that alleviates antimicrobial resistance","volume":"16","author":"Zhong","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Di Somma, A., Moretta, A., Can\u00e8, C., Cirillo, A., and Duilio, A. (2020). Antimicrobial and antibiofilm peptides. Biomolecules, 10.","DOI":"10.3390\/biom10040652"},{"key":"ref_173","first-page":"48","article-title":"Antimicrobial peptides: Mechanism of action, activity and clinical potential","volume":"8","author":"Zhang","year":"2021","journal-title":"Mil. Med. Res."},{"key":"ref_174","first-page":"baac011","article-title":"A review on antimicrobial peptides databases and the computational tools","volume":"2022","author":"Ramazi","year":"2022","journal-title":"Database J. Biol. Databases Curation"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1128\/CMR.00056-05","article-title":"Peptide antimicrobial agents","volume":"19","author":"Jenssen","year":"2006","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"106922","DOI":"10.1016\/j.bioorg.2023.106922","article-title":"Antimicrobial peptides fight against Pseudomonas aeruginosa at a sub-inhibitory concentration via anti-QS pathway","volume":"141","author":"Li","year":"2023","journal-title":"Bioorganic Chem."},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"Ridyard, K.E., Elsawy, M., Mattrasingh, D., Klein, D., Strehmel, J., and Beaulieu, C. (2023). Synergy between human peptide LL-37 and polymyxin B against planktonic and biofilm cells of Escherichia coli and Pseudomonas aeruginosa. Antibiotics, 12.","DOI":"10.3390\/antibiotics12020389"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"041002","DOI":"10.1116\/6.0001981","article-title":"New antimicrobial peptide-antibiotic combination strategy for Pseudomonas aeruginosa inactivation","volume":"17","author":"Han","year":"2022","journal-title":"Biointerphases"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"4903","DOI":"10.1128\/AAC.00311-13","article-title":"Antimicrobial peptide GL13K is effective in reducing biofilms of Pseudomonas aeruginosa","volume":"57","author":"Hirt","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"e00686-17","DOI":"10.1128\/AAC.00686-17","article-title":"Synergistic efficacy of Aedes aegypti antimicrobial peptide cecropin A2 and tetracycline against Pseudomonas aeruginosa","volume":"61","author":"Zheng","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s12967-025-06321-9","article-title":"Antimicrobial peptide biological activity, delivery systems and clinical translation status and challenges","volume":"23","author":"Zheng","year":"2025","journal-title":"J. Transl. Med."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1128\/AAC.50.2.819-821.2006","article-title":"In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients","volume":"50","author":"Traczewski","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/CCM.0b013e3181691b99","article-title":"Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: A multicenter, randomized study","volume":"36","author":"Chastre","year":"2008","journal-title":"Crit. Care Med."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1021\/acsinfecdis.8b00001","article-title":"Plazomicin retains antibiotic activity against most aminoglycoside modifying enzymes","volume":"4","author":"Cox","year":"2018","journal-title":"ACS Infect. Dis."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40265-019-1054-3","article-title":"Plazomicin: A novel aminoglycoside for the treatment of resistant Gram-negative bacterial infections","volume":"79","author":"Eljaaly","year":"2019","journal-title":"Drugs"},{"key":"ref_186","first-page":"277","article-title":"Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin","volume":"6","author":"Zhanel","year":"2012","journal-title":"Expert Rev. Anti-infective Ther."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s40265-020-01358-0","article-title":"Delafloxacin: A review in acute bacterial skin and skin structure infections","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Craddock, V.D., Steere, E.L., Harman, H., and Britt, N.S. (2023). Activity of delafloxacin and comparator fluoroquinolones against multidrug-resistant Pseudomonas aeruginosa in an in vitro cystic fibrosis sputum model. Antibiotics, 12.","DOI":"10.3390\/antibiotics12061078"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"e02529-16","DOI":"10.1128\/AAC.02529-16","article-title":"WCK 5107 (zidebactam) and WCK 5153 are novel inhibitors of PBP2 showing potent \u201c\u03b2-lactam enhancer\u201d activity against Pseudomonas aeruginosa, including multidrug-resistant metallo-\u03b2-lactamase-producing high-risk clones","volume":"61","author":"Moya","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"481651","DOI":"10.5402\/2013\/481651","article-title":"Health benefits of probiotics: A review","volume":"2013","author":"Kechagia","year":"2013","journal-title":"ISRN Nutr."},{"key":"ref_191","doi-asserted-by":"crossref","unstructured":"Huang, F.C., and Huang, S.C. (2024). The Hazards of Probiotics on Gut-Derived Pseudomonas aeruginosa Sepsis in Mice Undergoing Chemotherapy. Biomedicines, 12.","DOI":"10.3390\/biomedicines12020253"},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"Paterniti, I., Scuderi, S.A., Cambria, L., Nostro, A., Esposito, E., and Marino, A. (2024). Protective Effect of Probiotics against Pseudomonas aeruginosa Infection of Human Corneal Epithelial Cells. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25031770"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1164\/rccm.200607-1029OC","article-title":"A novel host defense system of airways is defective in cystic fibrosis","volume":"175","author":"Moskwa","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_194","unstructured":"Alaxia SAS (2009). Orphan designation EU\/3\/09\/654: Hypothiocyanite\/Lactoferrin for the treatment of cystic fibrosis. EMA Hum. Med. Orphan Des., EMA\/COMP\/392984\/2009."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/jac\/dku357","article-title":"Combination of hypothiocyanite and lactoferrin (ALX-109) enhances the ability of tobramycin and aztreonam to eliminate Pseudomonas aeruginosa biofilms growing on cystic fibrosis airway epithelial cells","volume":"70","author":"Coutermarsh","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"e02332-19","DOI":"10.1128\/AAC.02332-19","article-title":"Hydrogen peroxide-generating electrochemical scaffold activity against trispecies biofilms","volume":"64","author":"Raval","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41522-016-0003-0","article-title":"Eradication of Pseudomonas aeruginosa biofilms and persister cells using an electrochemical scaffold and enhanced antibiotic susceptibility","volume":"2","author":"Sultana","year":"2016","journal-title":"npj Biofilms Microbiomes"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"e01216-23","DOI":"10.1128\/aac.01216-23","article-title":"HOCl-producing electrochemical bandage for treating Pseudomonas aeruginosa-infected murine wounds","volume":"68","author":"Fleming","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"e00626-24","DOI":"10.1128\/spectrum.00626-24","article-title":"HOCl-producing electrochemical bandage is active in murine polymicrobial wound infection","volume":"12","author":"Fleming","year":"2024","journal-title":"Microbiol. Spectr."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/1\/163\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T16:17:09Z","timestamp":1768321029000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/1\/163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":199,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["medicina62010163"],"URL":"https:\/\/doi.org\/10.3390\/medicina62010163","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]}}}